Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_assertion evidence source_evidence_literature NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_assertion SIO_000772 14755889 NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_assertion wasDerivedFrom befree-2016 NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_assertion wasGeneratedBy ECO_0000203 NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.
- befree-2016 importedOn "2016-02-19" NP430301.RA71H9la1i0sr1FGxt0VcGryl2SeY4xAhdV_2Z0g8Y9AM130_provenance.